Page 2 - Saran Saund News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Saran saund. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Saran Saund Today - Breaking & Trending Today

US firm launches telemedicine platform to support drug product for India

US firm launches telemedicine platform to support respiratory health in India
US firm launches telemedicine platform to support respiratory health in India
03 February 2021 | News
Source credit: PulmoHeal
Mateon Therapeutics, Inc, a US based developer of TGF-β therapeutics for oncology and infectious diseases, has announced that it has launched its artificial intelligence (AI) telemedicine platform for post marketing survey (PMS) to support the launch of its drug product, PulmoHeal
TM.
TM, rounds out the company’s AI telemedicine solution.
The combination of the drug and telemedicine targets patients for respiratory health, including COVID-19, in India. Initially the drug and device combination will only be available in India through Indian partner, Windlas, with the drug marketed under brand name PulmoHeal ....

Saran Saund , Hitesh Windlas , Amit Shah , Mike Potts , Ai Division , Mateon Therapeutics Inc , Mateon Therapeutics , Artificial Intelligence , சரண் சாண்ட் , ஹிடேஷ் விண்ட்லாஸ் , அமித் ஷா , மைக் பாட்ஸ் , ஐ பிரிவு , செயற்கை உளவுத்துறை ,

Mateon launches telemedicine platform to support its drug, PulmoHeal

US firm launches telemedicine platform to support respiratory health in India
US firm launches telemedicine platform to support respiratory health in India
03 February 2021 | News
Source credit: PulmoHeal
Mateon Therapeutics, Inc, a US based developer of TGF-β therapeutics for oncology and infectious diseases, has announced that it has launched its artificial intelligence (AI) telemedicine platform for post marketing survey (PMS) to support the launch of its drug product, PulmoHeal
TM.
TM, rounds out the company’s AI telemedicine solution.
The combination of the drug and telemedicine targets patients for respiratory health, including COVID-19, in India. Initially the drug and device combination will only be available in India through Indian partner, Windlas, with the drug marketed under brand name PulmoHeal ....

Saran Saund , Hitesh Windlas , Amit Shah , Mike Potts , Ai Division , Mateon Therapeutics Inc , Mateon Therapeutics , Artificial Intelligence , சரண் சாண்ட் , ஹிடேஷ் விண்ட்லாஸ் , அமித் ஷா , மைக் பாட்ஸ் , ஐ பிரிவு , செயற்கை உளவுத்துறை ,

MATEON ANNOUNCES POSITIVE INTERIM RESULTS FROM ARTI-19 CLINICAL TRIAL EVALUATING COVID-19 ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
MATEON ANNOUNCES POSITIVE INTERIM RESULTS FROM ARTI-19 CLINICAL TRIAL EVALUATING COVID-19 .
Mateon Therapeutics, Inc.January 13, 2021 GMT
AGOURA HILLS, California, Jan. 13, 2021 (GLOBE NEWSWIRE) Mateon Therapeutics, Inc. (OTCQB: MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and COVID-19, reported positive interim results from its ARTI-19 clinical trial evaluating ARTIVedaTM against COVID-19.
“These interim results suggest that ARTIVeda is a well-tolerated and effective treatment for COVID-19 that produces a faster recovery time when compared to Standard of Care alone,” said Dr. Vuong Trieu, Chairman and CEO of Mateon. ....

United States , India Ministry , United Kingdom , Andhra Pradesh , Republic Of , Agoura Hills , Sri Lanka , Saran Saund , Amit Shah , Vuong Trieu , Chhatrapati Pramila Raje , Wanjun Chen , Suhas Kshirsagar , Health Services , Government Of India Ministry Health , Rajarshi Chhatrapati Shahu Maharaj Government Medical College , Mateon Therapeutics Inc , Government Medical College , Windlas Biotech Private Limited India , Windlas Biotech Private Limited , Emergency Use Authorization , Chief Business Officer , Ayurvedic Healing , Integrative Wellness Clinic , Mucosal Immunology Section , Clinical Trials Registry India ,

MATEON ANNOUNCES POSITIVE INTERIM RESULTS FROM ARTI-19 CLINICAL TRIAL EVALUATING COVID-19 THERAPEUTIC

MATEON ANNOUNCES POSITIVE INTERIM RESULTS FROM ARTI-19 CLINICAL TRIAL EVALUATING COVID-19 THERAPEUTIC
Mateon Therapeutics, Inc.
ARTI-19 CLINICAL TRIAL EVALUATING COVID-19 THERAPEUTIC
AGOURA HILLS, California, Jan. 13, 2021 (GLOBE NEWSWIRE) Mateon Therapeutics, Inc. (OTCQB: MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and COVID-19, reported positive interim results from its ARTI-19 clinical trial evaluating ARTIVeda
TM against COVID-19.
“These interim results suggest that ARTIVeda is a well-tolerated and effective treatment for COVID-19 that produces a faster recovery time when compared to Standard of Care alone,” said Dr. Vuong Trieu, Chairman and CEO of Mateon.
ARTIVeda is Mateon’s lead Ayurvedic drug against COVID-19 in India and is being developed by Mateon in partnership with Windlas Biotech Private Limited (India). ARTI-19 India is being conducted by Windlas as part of Mateon’s global effort to deploy ARTIVe ....

United States , India Ministry , United Kingdom , Andhra Pradesh , Republic Of , Agoura Hills , Sri Lanka , Saran Saund , Amit Shah , Vuong Trieu , Mateon Oncotelic , Chhatrapati Pramila Raje , Wanjun Chen , Suhas Kshirsagar , Health Services , Government Of India Ministry Health , Rajarshi Chhatrapati Shahu Maharaj Government Medical College , Mateon Therapeutics Inc , Government Medical College , Windlas Biotech Private Limited India , Mateon Therapeutics , Windlas Biotech Private Limited , Emergency Use Authorization , Chief Business Officer , Ayurvedic Healing , Integrative Wellness Clinic ,